Glybera

Type: Product
Name: Glybera
First reported Sep 14 2014 - Updated Sep 14 2014 - 1 reports

Gene Therapies Push Investors to Examine New Areas of Human Body

Advances in gene therapy are leading venture investors to fund treatments for conditions affecting a wider range of body systems. Venture firms have sunk more dollars into gene therapies since 2010, $715.8 million, than they did all of last decade, ... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 3 reports

Rare Disease Biotech Xenon Pharmaceuticals Inc. Files For $52 Million IPO

Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. Xenon has a number of collaboration and licensing agreements ... [Published BioSpace - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Novel Gene Therapy Payment Model Proposed

Assurances NeededDrs. Wilson and Brennan note that while a liver transplant, for example, can cost up to $300,000, physicians and hospitals that “transplant livers know they will be compensated at market rates through existing contracts. Gene developers ... [Published Genetic Engineering News - Sep 10 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015

Welcome to the latest edition of our weekly EuroBiotech Report . Having spent much of 2014 touting the potential of its clinical-stage oncology candidates, AstraZeneca ( $AZN ) struck a deal with Redx Pharma to work on the next generation of cancer drugs. ... [Published FierceBiotech - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 1 reports

Human medicines European public assessment report (EPAR): Glybera, alipogene tiparvovec, Revision: 1, Authorised

First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

UniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs

AMSTERDAM, the Netherlands, Sept. 2, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the second quarter of 2014 and an update on multiple gene therapy programs.Corporate HighlightsPipeline ... [Published BusinessWeek - Sep 02 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

uniQure Expands Gene Therapy Stable with InoCard Acquisition

uniQure , which boasts the first and only gene therapy product to receive regulatory approval in the EU, Glybera , has acquired InoCard, an early-stage biotechnology company focused on the development of gene therapy products for cardiac disease. The ... [Published Genetic Engineering News - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

uniQure Acquires Cardiology Gene Therapy Company InoCard

--Combination of uniQure Leadership and Fundamental InoCard Discovery May Enable Transformative Gene Therapy Treatment of Congestive Heart Failure--Amsterdam, the Netherlands, and Heidelberg, Germany, August 11, 2014 - uniQure N.V. (NASDAQ: QURE), a leader ... [Published Noodls - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Advanced therapy medicinal products

This article summarises what advanced therapy medicinal products (ATMPs) are, how their regulation is performed and the associated challenges, and discusses some of ATMPs registered in Europe and their therapeutic usesTiene Bauters PharmD PhDClinical ... [Published Hospital Pharmacy Europe - Aug 08 2014]
Entities: Cartilage, ATMP, Lipoprotein
First reported Jun 18 2014 - Updated Jun 19 2014 - 2 reports

uniQure, Medison sign distribution agreement for Glybera

uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ... [Published PBR - News - Jun 19 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

[tt] [GRG] NewAbs: Genome Editing to Cure AIDS

To Members and Friends of the Los Angeles Gerontology Research Group:         Genome editing to cure disease... -- Steve Coles " Can Genome Editing Cure AIDS? " by Hank Greely, Center for Law and Biosciences at Stanford Law School and by ... [Published TranshumanTech - Mar 27 2014]
Entities: Genome, HIV/AIDS, Mutation
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Gene Expression Analysis Market (Gene Profiling, Bioinformatics, Data Analysis Software) worth $4.3 Billion by 2018 - New Report by MarketsandMarkets

This report broadly categorizes the global gene expression analysis market into three segments, namely, instrumentation, consumables, and services. According to the new market research report, “Gene Expression Analysis Market by Technology (DNA Microarray, ... [Published PRWeb - Mar 27 2014]

Quotes

"We have decided to move ahead with this potential indication as creating a total posterior vitreous detachment--which can be achieved with Jetrea--is accepted as an important step in preventing further revascularisation in proliferative diabetic retinopathy" ThromboGenics CEO Dr. Patrik De Haes said...
Jörn Aldag, uniQure Chief Executive Officer, commented: "uniQure is steadily executing its strategy of building a valuable clinical and pre-clinical pipeline from its gene therapy platform. We made major progress toward the achievement of preclinical, clinical, and corporate development goals, which we view to be essential to maintain our position at the forefront of gene therapy. In the second half of the year, we are focused on the start of the hemophilia B clinical trial."
...and suddenly public markets are interested--private markets too," he said, adding that even Big Pharma has begun to make some noise in the field. "In a way it resembles what you may have seen with silencing technology and with antibodies."
...Patrick Most, founder of InoCard. "We believe that combining our promising S100A1 therapy with uniQure's capabilities in innovating safe and effective gene therapies has the potential to transform the treatment of cardiovascular diseases."

More Content

All (25) | News (15) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Gene Therapies Push Investors to Examine New Ar... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
Xenon pitches Genentech, Teva 'extreme genetics... [Published FierceBiotech - Sep 10 2014]
Rare Disease Biotech Xenon Pharmaceuticals Inc.... [Published BioSpace - Sep 10 2014]
Rare disease biotech Xenon Pharmaceuticals file... [Published Renaissance Capital - Sep 10 2014]
Rare disease biotech Xenon Pharmaceuticals file... [Published Nasdaq - Sep 10 2014]
Novel Gene Therapy Payment Model Proposed [Published Genetic Engineering News - Sep 10 2014]
AZ strikes Alderley cancer pact, Cerenis mulls ... [Published FierceBiotech - Sep 04 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Sep 03 2014]
uniQure Announces Results for the Second Quarte... [Published Virtual Strategy Magazine - Sep 02 2014]
UniQure Announces Results for the Second Quarte... [Published BusinessWeek - Sep 02 2014]
uniQure Expands Gene Therapy Stable with InoCar... [Published Genetic Engineering News - Aug 12 2014]
UniQure bets on a gene therapy for heart failure [Published FierceBiotech - Aug 11 2014]
uniQure Acquires Cardiology Gene Therapy Compan... [Published Noodls - Aug 11 2014]
Advanced therapy medicinal products [Published Hospital Pharmacy Europe - Aug 08 2014]
Chiesi and uniQure Provide Update on Glybera(r)... [Published GlobeNewswire: Acquisitions News - Aug 04 2014]
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
uniQure and Medison Sign Glybera Distribution A... [Published PR Newswire - Jun 18 2014]
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
Gene Expression Analysis Market (Gene Profiling... [Published PRWeb - Mar 27 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
Dutch gene therapy pioneer raises $82 mln in U.... [Published PE Hub Blog - Feb 06 2014]
Europe: Early Communications with Regulators is... [Published Pharmaceutical Executive - Jan 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Gene Therapies Push Investors to Examine New Ar... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
Advances in gene therapy are leading venture investors to fund treatments for conditions affecting a wider range of body systems. Venture firms have sunk more dollars into gene therapies since 2010, $715.8 million, than they did all of last decade, ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Sep 03 2014]
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ...
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Genome editing to cure disease... -- Steve Coles " Can Genome Editing Cure AIDS? " by Hank Greely, Center for Law and Biosciences at Stanford Law School and by ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1 2

Press Releases

sort by: Date | Relevance
Chiesi and uniQure Provide Update on Glybera(r)... [Published GlobeNewswire: Acquisitions News - Aug 04 2014]
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.